Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of subcutaneous CM313 alone and in combination in relapsed/refractory multiple myeloma
CTR20233843Phase 2Active
- Sponsor
- Keymed Biosciences
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of cm313 in multiple myeloma (MM), sponsored by Keymed Biosciences. Started Feb 2024; status: active.
02
Drugs
cm313
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20233843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233843.